GlassScriptPhysician profile
Jeffrey K Gross
NPI 1053343327
$1,192.89
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $52.18 · 2021: $103 · 2022: $484 · 2023: $112 · 2024: $31.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.37 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.69 | 2019-2020 | |
| Biogen, INC. | $81.78 | 2019 | |
| Exeltis, USA INC. | $70.06 | 2021-2024 | Slynd |
| Therapeuticsmd, INC. | $68.57 | 2019-2022 | |
| Hologic Sales and Service, LLC | $64.38 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $62.68 | 2021-2023 | |
| Scynexis, INC. | $61.57 | 2022 | |
| Avanos Medical | $49.79 | 2019 | |
| Evofem Biosciences, INC. | $42.79 | 2021-2022 | |
| Myovant Sciences INC. | $32.75 | 2022 | |
| Pfizer INC. | $30.21 | 2019-2022 | |
| Astellas Pharma US INC | $29.10 | 2023-2024 | Veozah |
| Allergan, INC. | $28.91 | 2019 | |
| Covidien LP | $25.29 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $25.14 | 2019-2023 | Paragard T 380a |
| Smith+Nephew, INC. | $18.28 | 2019 | |
| Becton, Dickinson and Company | $18.10 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.76 | 2019 | |
| Merck Sharp & Dohme LLC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.